黄芪甲苷防治肝脏疾病的药理作用及其机制

付珂; 代书; 游娟; 杨晨; 李晓莉; 曾莉; 蒲诗云

doi:10.12449/JCH251032

黄芪甲苷防治肝脏疾病的药理作用及其机制

DOI: 10.12449/JCH251032

付珂¹,
代书²,
游娟¹,
杨晨¹,
李晓莉¹,
曾莉¹,
蒲诗云^1, , ,

1.
成都市第五人民医院药剂科，成都 611130
2.
成都中医药大学药学院，成都 611137

基金项目:

国家自然科学基金 (82003828);

委校联合创新基金项目 (WXLH202402028);

四川省中医药管理局基金项目 (2022CP7147)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：付珂负责课题设计，撰写论文；代书、游娟、杨晨、李晓莉参与数据收集与分析；曾莉、蒲诗云负责修改论文并最后定稿。

详细信息

通信作者:
蒲诗云， pushiyun@cdutcm.edu.cn （ORCID： 0000-0002-0907-6664）

计量
- 文章访问数: 54
- HTML全文浏览量: 30
- PDF下载量: 9
- 被引次数: 0
出版历程
- 收稿日期: 2025-03-17
- 录用日期: 2025-04-08
- 出版日期: 2025-10-25

Pharmacological action of astragaloside Ⅳ in the prevention and treatment of liver diseases and its mechanism

Ke FU¹,
Shu DAI²,
Juan YOU¹,
Chen YANG¹,
Xiaoli LI¹,
Li ZENG¹,
Shiyun PU^{1
, ,
,}

1.
Department of Pharmacy，The Fifth People’s Hospital of Chengdu，Chengdu 611130，China
2.
School of Pharmacy，Chengdu University of Traditional Chinese Medicine，Chengdu 611137，China

Research funding:

National Natural Science Foundation of China (82003828);

Commission-University Joint Innovation Foundation (WXLH202402028);

Sichuan Provincial Administration of Traditional Chinese Medicine Fund (2022CP7147)

More Information

Corresponding author: PU Shiyun， pushiyun@cdutcm.edu.cn （ORCID： 0000-0002-0907-6664）

摘要

摘要: 黄芪甲苷（AS-Ⅳ）是一种来源于黄芪的三萜皂苷类天然化合物，在调控肝脏疾病方面展现出重要潜力。本文系统梳理并总结了AS-Ⅳ在肝脏疾病研究领域的国内外最新进展，发现AS-Ⅳ可通过调节脂质代谢、抗肿瘤、抗炎、抗纤维化及调节肠道菌群等途径发挥对肝脏的保护作用。其作用机制涉及多条信号传导通路，包括AMPK、NLRP3、NF-κB、JAK2/STAT3和Nrf2等。这些研究成果为基于天然产物AS-Ⅳ开发保肝药物或相关功能性食品提供了科学依据。
- 肝疾病 /
- 黄芪甲苷 /
- 药理作用分子作用机制
Abstract: Astragaloside Ⅳ （AS-Ⅳ） is a natural triterpenoid saponin compound derived from Astragalus membranaceus and has shown significant potential in the regulation of liver diseases. This article reviews the latest research advances in AS-Ⅳ in the field of liver diseases in China and globally， and it is found that AS-Ⅳ exerts a liver-protecting effect by regulating lipid metabolism， exerting an anti-tumor/anti-inflammatory/anti-fibrotic effect， and modulating gut microbiota. Its mechanism of action involves multiple signaling pathways， such as AMPK， NLRP3， NF-κB， JAK2/STAT3， and Nrf2. These research findings provide a scientific basis for the development of liver-protecting drugs or functional foods based on the natural product AS-Ⅳ.
- Liver Diseases /
- Astragaloside Ⅳ /
- Molecular Mechanisms of Pharmacological Action

HTML全文

图 1 AS-Ⅳ治疗肝脏疾病的药理作用及靶点

Figure 1. Pharmacological effects and targets of AS-Ⅳ in the treatment of liver diseases

下载: 全尺寸图片幻灯片

参考文献(50)

[1]	WANG FS, FAN JG, ZHANG Z, et al. The global burden of liver disease: The major impact of China[J]. Hepatology, 2014, 60( 6): 2099- 2108. DOI: 10.1002/hep.27406.
[2]	DEVARBHAVI H, ASRANI SK, ARAB JP, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023, 79( 2): 516- 537. DOI: 10.1016/j.jhep.2023.03.017.
[3]	SHI H, ZHOU P, GAO G, et al. Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway[J]. J Food Biochem, 2021, 45( 7): e13757. DOI: 10.1111/jfbc.13757.
[4]	SHEN Q, FANG J, GUO H, et al. Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease[J]. Free Radic Biol Med, 2023, 203: 45- 57. DOI: 10.1016/j.freeradbiomed.2023.03.022.
[5]	GUO JN, LE YF, YUAN AN, et al. Astragaloside IV ameliorates cisplatin-induced liver injury by modulating ferroptosis-dependent pathways[J]. J Ethnopharmacol, 2024, 328: 118080. DOI: 10.1016/j.jep.2024.118080.
[6]	LIU X, DING YP, JIANG CX, et al. Astragaloside IV ameliorates radiation-induced nerve cell damage by activating the BDNF/TrkB signaling pathway[J]. Phytother Res, 2023, 37( 9): 4102- 4116. DOI: 10.1002/ptr.7872.
[7]	WANG JY, PU XY, ZHUANG HW, et al. Astragaloside IV alleviates septic myocardial injury through DUSP1-Prohibitin 2 mediated mitochondrial quality control and ER-autophagy[J]. J Adv Res, 2025, 75: 561- 580. DOI: 10.1016/j.jare.2024.10.030.
[8]	KIM J, YANG G, KIM Y, et al. AMPK activators: Mechanisms of action and physiological activities[J]. Exp Mol Med, 2016, 48( 4): e224. DOI: 10.1038/emm.2016.16.
[9]	ZHOU M, LIU X, WU YJ, et al. Mechanism of astragaloside Ⅳ on db/db mice with type 2 diabetes mellitus and non-alcoholic fatty liver disease based on AMPK signaling pathway[J]. Chin J Exp Tradit Med Form, 2024, 30( 5): 72- 79. DOI: 10.13422/j.cnki.syfjx.20232039. 周敏, 刘秀, 吴勇军, 等. 基于AMPK信号通路探讨黄芪甲苷对db/db小鼠2型糖尿病合并非酒精性脂肪肝病的作用机制[J]. 中国实验方剂学杂志, 2024, 30( 5): 72- 79. DOI: 10.13422/j.cnki.syfjx.20232039.
[10]	ZHOU B, ZHOU DL, WEI XH, et al. Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation[J]. Acta Pharmacol Sin, 2017, 38( 7): 998- 1008. DOI: 10.1038/aps.2016.175.
[11]	AJOOLABADY A, KAPLOWITZ N, LEBEAUPIN C, et al. Endoplasmic reticulum stress in liver diseases[J]. Hepatology, 2023, 77( 2): 619- 639. DOI: 10.1002/hep.32562.
[12]	WANG M, KAUFMAN RJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease[J]. Nature, 2016, 529( 7586): 326- 335. DOI: 10.1038/nature17041.
[13]	LEBEAUPIN C, VALLÉE D, HAZARI Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease[J]. J Hepatol, 2018, 69( 4): 927- 947. DOI: 10.1016/j.jhep.2018.06.008.
[14]	LEE JH, LEE J. Endoplasmic reticulum(ER) stress and its role in pancreatic β-cell dysfunction and senescence in type 2 diabetes[J]. Int J Mol Sci, 2022, 23( 9): 4843. DOI: 10.3390/ijms23094843.
[15]	JALAL IA, ELKHOELY A, MOHAMED SK, et al. Linagliptin and secoisolariciresinol diglucoside attenuate hyperlipidemia and cardiac hypertrophy induced by a high-methionine diet in rats via suppression of hyperhomocysteinemia-induced endoplasmic reticulum stress[J]. Front Pharmacol, 2023, 14: 1275730. DOI: 10.3389/fphar.2023.1275730.
[16]	GLICK D, BARTH S, MACLEOD KF. Autophagy: Cellular and molecular mechanisms[J]. J Pathol, 2010, 221( 1): 3- 12. DOI: 10.1002/path.2697.
[17]	XIAO ZL, LU CX, ZHOU DN, et al. Role of lipophagy in the prevention and treatment of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2024, 40( 7): 1450- 1458. DOI: 10.12449/JCH240725. 肖智利, 卢晨霞, 周丹妮, 等. 脂肪自噬在非酒精性脂肪性肝病防治中的作用[J]. 临床肝胆病杂志, 2024, 40( 7): 1450- 1458. DOI: 10.12449/JCH240725.
[18]	SINHA RA. Autophagy: A cellular guardian against hepatic lipotoxicity[J]. Genes(Basel), 2023, 14( 3): 553. DOI: 10.3390/genes14030553.
[19]	ZHU YF, SU Y, ZHANG J, et al. Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR-mediated autophagy[J]. Mol Med Rep, 2021, 23( 6): 437. DOI: 10.3892/mmr.2021.12076.
[20]	LIU G, WANG YH, ZHANG T, et al. Astragaloside-IV promotes autophagy via the Akt/mTOR pathway to improve cellular lipid deposition[J]. Medicine(Baltimore), 2024, 103( 16): e37846. DOI: 10.1097/MD.0000000000037846.
[21]	MANSOURI A, GATTOLLIAT CH, ASSELAH T. Mitochondrial dysfunction and signaling in chronic liver diseases[J]. Gastroenterology, 2018, 155( 3): 629- 647. DOI: 10.1053/j.gastro.2018.06.083.
[22]	LUO ZX, WANG YQ, XUE MZ, et al. Astragaloside IV ameliorates fat metabolism in the liver of ageing mice through targeting mitochondrial activity[J]. J Cell Mol Med, 2021, 25( 18): 8863- 8876. DOI: 10.1111/jcmm.16847.
[23]	VALENTA T, HAUSMANN G, BASLER K. The many faces and functions of β-catenin[J]. EMBO J, 2012, 31( 12): 2714- 2736. DOI: 10.1038/emboj.2012.150.
[24]	HE T, WANG FF, LIU ZQ, et al. Astragaloside affects HepG-2 cell proliferation and apoptosis through Wnt/β-catenin pathway[J]. World Chin Med, 2020, 15( 24): 3787- 3791. DOI: 10.3969/j.issn.1673-7202.2020.24.011. 何婷, 王斐斐, 柳仲秋, 等. 黄芪甲苷通过Wnt/β-catenin途径影响HepG-2细胞的增殖和凋亡[J]. 世界中医药, 2020, 15( 24): 3787- 3791. DOI: 10.3969/j.issn.1673-7202.2020.24.011.
[25]	QIN CD, MA DN, REN ZG, et al. Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3β/β-catenin pathway[J]. Oncol Rep, 2017, 37( 3): 1725- 1735. DOI: 10.3892/or.2017.5389.
[26]	FOLKMAN J. Angiogenesis[J]. Annu Rev Med, 2006, 57: 1- 18. DOI: 10.1146/annurev.med.57.121304.131306.
[27]	ZHANG S, TANG DC, ZANG WH, et al. Synergistic inhibitory effect of traditional Chinese medicine astragaloside IV and curcumin on tumor growth and angiogenesis in an orthotopic nude-mouse model of human hepatocellular carcinoma[J]. Anticancer Res, 2017, 37( 2): 465- 473. DOI: 10.21873/anticanres.11338.
[28]	OGIHARA T, MIZOI K, KAMIOKA H, et al. Physiological roles of ERM proteins and transcriptional regulators in supporting membrane expression of efflux transporters as factors of drug resistance in cancer[J]. Cancers(Basel), 2020, 12( 11): 3352. DOI: 10.3390/cancers12113352.
[29]	LESLIE EM, DEELEY RG, COLE SPC. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP(ABCG2) in tissue defense[J]. Toxicol Appl Pharmacol, 2005, 204( 3): 216- 237. DOI: 10.1016/j.taap.2004.10.012.
[30]	QU XY, GAO H, ZHAI JH, et al. Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2[J]. Eur J Pharm Sci, 2020, 148: 105325. DOI: 10.1016/j.ejps.2020.105325.
[31]	FU YJ, MACKOWIAK B, FENG DC, et al. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression[J]. Gut, 2023, 72( 10): 1942- 1958. DOI: 10.1136/gutjnl-2022-327924.
[32]	YUAN ML, ZHANG XS, YUE FX, et al. CircNOLC1 promotes colorectal cancer liver metastasis by interacting with AZGP1 and sponging miR-212-5p to regulate reprogramming of the oxidative pentose phosphate pathway[J]. Adv Sci(Weinh), 2023, 10( 33): e2205229. DOI: 10.1002/advs.202205229.
[33]	DINAMI R, POMPILI L, PETTI E, et al. MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer[J]. EMBO Mol Med, 2023, 15( 1): e16033. DOI: 10.15252/emmm.202216033.
[34]	MA Y, LI Y, WU TT, et al. Astragaloside IV attenuates programmed death-ligand 1-mediated immunosuppression during liver cancer development via the miR-135b-5p/CNDP1 axis[J]. Cancers(Basel), 2023, 15( 20): 5048. DOI: 10.3390/cancers15205048.
[35]	MIN YQ, LI S, LIU XH, et al. Research advances in the cascade interaction between reactive oxygen species/reactive nitrogen species and the NF-κB signaling pathway in liver fibrosis[J]. J Clin Hepatol, 2023, 39( 6): 1454- 1460. DOI: 10.3969/j.issn.1001-5256.2023.06.031. 闵远骞, 李姗, 刘湘花, 等. 活性氧/活性氮与NF-κB信号通路级联交互在肝纤维化中的作用[J]. 临床肝胆病杂志, 2023, 39( 6): 1454- 1460. DOI: 10.3969/j.issn.1001-5256.2023.06.031.
[36]	CHENG MX, CHEN ZZ, CAI YL, et al. Astragaloside IV protects against ischemia reperfusion in a murine model of orthotopic liver transplantation[J]. Transplant Proc, 2011, 43( 5): 1456- 1461. DOI: 10.1016/j.transproceed.2011.02.066.
[37]	LIU YL, ZHANG QZ, WANG YR, et al. Astragaloside IV improves high-fat diet-induced hepatic steatosis in nonalcoholic fatty liver disease rats by regulating inflammatory factors level via TLR4/NF-κB signaling pathway[J]. Front Pharmacol, 2021, 11: 605064. DOI: 10.3389/fphar.2020.605064.
[38]	FU JN, WU H. Structural mechanisms of NLRP3 inflammasome assembly and activation[J]. Annu Rev Immunol, 2023, 41: 301- 316. DOI: 10.1146/annurev-immunol-081022-021207.
[39]	WU S, WEN F, ZHONG XB, et al. Astragaloside IV ameliorate acute alcohol-induced liver injury in mice via modulating gut microbiota and regulating NLRP3/caspase-1 signaling pathway[J]. Ann Med, 2023, 55( 1): 2216942. DOI: 10.1080/07853890.2023.2216942.
[40]	DING YP, DONG XQ, YIFAN MA, et al. Astragaloside IV plays a role in reducing radiation-induced liver inflammation in mice by inhibiting thioredoxin-interacting protein/nod-like receptor protein 3 signaling pathway[J]. J Tradit Chin Med, 2023, 43( 1): 87- 94. DOI: 10.19852/j.cnki.jtcm.2023.01.008.
[41]	QU XY, GAO H, TAO LN, et al. Astragaloside IV protects against cisplatin-induced liver and kidney injury via autophagy-mediated inhibition of NLRP3 in rats[J]. J Toxicol Sci, 2019, 44( 3): 167- 175. DOI: 10.2131/jts.44.167.
[42]	YAN Y, ZHANG LB, MA R, et al. Jolkinolide B ameliorates rheumatoid arthritis by regulating the JAK2/STAT3 signaling pathway[J]. Phytomedicine, 2024, 124: 155311. DOI: 10.1016/j.phymed.2023.155311.
[43]	ZHANG HY, CHANG XR. Astragaloside Ⅳ inhibits JAK2/STAT3 signaling pathway and alleviates severe acute pancreatitis-associated acute liver injury in rats[J]. Chin J Pathophysiol, 2016, 32( 6): 984- 989. DOI: 10.3969/j.issn.1000-4718.2016.06.004. 张海云, 常香荣. 黄芪甲苷通过抑制JAK2/STAT3信号通路减轻重症急性胰腺炎大鼠肝损伤[J]. 中国病理生理杂志, 2016, 32( 6): 984- 989. DOI: 10.3969/j.issn.1000-4718.2016.06.004.
[44]	LI XM, WANG XL, HAN CY, et al. Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p38 MAPK pathway[J]. Free Radic Biol Med, 2013, 60: 168- 176. DOI: 10.1016/j.freeradbiomed.2013.02.027.
[45]	ZHAO XM, ZHANG J, LIANG YN, et al. Astragaloside IV synergizes with ferulic acid to alleviate hepatic fibrosis in bile duct-ligated cirrhotic rats[J]. Dig Dis Sci, 2020, 65( 10): 2925- 2936. DOI: 10.1007/s10620-019-06017-3.
[46]	EZHILARASAN D. Hepatic stellate cells in the injured liver: Perspectives beyond hepatic fibrosis[J]. J Cell Physiol, 2022, 237( 1): 436- 449. DOI: 10.1002/jcp.30582.
[47]	WANG SG, LI JY, HUANG H, et al. Anti-hepatitis B virus activities of astragaloside IV isolated from Radix Astragali[J]. Biol Pharm Bull, 2009, 32( 1): 132- 135. DOI: 10.1248/bpb.32.132.
[48]	ZHAI YY, ZHOU WL, YAN X, et al. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling[J]. Phytomedicine, 2022, 107: 154444. DOI: 10.1016/j.phymed.2022.154444.
[49]	NIU KQ, CHANG H, LYU GF, et al. Inhibitory effect of astragaloside Ⅳ on cisplatin-induced liver injury in mice and its mechanism[J]. J Jilin Univ(Med Ed), 2025, 51( 2): 370- 377. DOI: 10.13481/j.1671-587X.20250211. 牛凯琦, 昌贺, 律广富, 等. 黄芪甲苷对顺铂所致小鼠肝损伤的抑制作用及其机制[J]. 吉林大学学报(医学版), 2025, 51( 2): 370- 377. DOI: 10.13481/j.1671-587X.20250211.
[50]	LI L, HUANG WX, WANG SK, et al. Astragaloside IV attenuates acetaminophen-induced liver injuries in mice by activating the Nrf2 signaling pathway[J]. Molecules, 2018, 23( 8): 2032. DOI: 10.3390/molecules23082032.